Cleared Traditional

K111387 - LIAT (TM) INFLUENZA A / B ASSAY, LIAT (TM) ANALYZER

K111387 is an FDA 510(k) clearance for LIAT (TM) INFLUENZA A / B ASSAY, manufactured by Iquum, Inc.. The device is a Class 2 Microbiology device with product code OCC cleared through the Traditional 510(k) pathway after a 79-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2011
Decision
79d
Days
Class 2
Risk

K111387 is an FDA 510(k) clearance for the LIAT (TM) INFLUENZA A / B ASSAY, LIAT (TM) ANALYZER. Classified as Respiratory Virus Panel Nucleic Acid Assay System (product code OCC), Class II - Special Controls.

Submitted by Iquum, Inc. (Marlborough, US). The FDA issued a Cleared decision on August 4, 2011 after a review of 79 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3980 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Iquum, Inc. devices

FDA 510(k) Submission Details - K111387

510(k) Number K111387 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 17, 2011
Decision Date August 04, 2011
Days to Decision 79 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
23d faster than avg
Panel avg: 102d · This submission: 79d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

OCC Device Classification - Class 2, Special Controls

Product Code OCC Respiratory Virus Panel Nucleic Acid Assay System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3980
Definition A Respiratory Viral Panel Multiplex Nucleic Acid Assay Is A Qualitative In Vitro Diagnostic Device Intended To Simultaneously Detect And Identify Multiple Viral Nucleic Acids Extracted From Human Respiratory Specimens Or Viral Culture. The Detection And Identification Of A Specific Viral Nucleic Acid From Individuals Exhibiting Signs And Symptoms Of Respiratory Infection Aids In The Diagnosis Of Respiratory Viral Infection When Used In Conjunction With Other Clinical And Laboratory Findings. The Device Is Intended For Detection And Identification Of A Combination Of The Following Viruses: Influenza A And Influenza B, Influenza A Subtype H1 And Influenza A Subtype H3, Respiratory Syncytial Virus Subtype A And Respiratory Syncytial Virus Subtype B, Parainfluenza 1, Parainfluenza 2, And Parainfluenza 3 Virus, Human Metapneumovirus, Rhinovirus, And Adenovirus.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - OCC Respiratory Virus Panel Nucleic Acid Assay System

All 72
Devices cleared under the same product code (OCC) and FDA review panel - the closest regulatory comparables to K111387.
QUIDEL MOLECULAR INFLUENZA A + B ASSAY
K112172 · Quidel Corp. · Dec 2011
JBAIDS INFLUENZA A&B DETECTION KIT
K111775 · U.S. Army Medical Material Development Acitvity · Sep 2011
XTAG RESPIRATORY VIRAL PANEL, XTAG DATA ANALYSIS SOFTWARE (TDAS RVP-1)
K112199 · Luminex Molecular Diagnostics, Inc. · Sep 2011
XTAG RESPIRATORY VIRAL PANEL FAST, XTAG DATA ANALYSIS SOFTWARE FOR RVP FAST
K103776 · Luminex Molecular Diagnostics, Inc. · Jul 2011
PROFLU+ ASSAY
K110968 · Gen-Probe Prodesse, Inc. · Jun 2011
FILMARRAY RP PANEL
K110764 · Idaho Technology, Inc. · Apr 2011